J. Goldman & Co’s BioMarin Pharmaceuticals BMRN Stock Holding History

J. Goldman & Co’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-31,701	Closed	-$2.61M	–	472
2024 Q2	$2.61M	Sell	31,701 -101,682	-76%	-$8.47M	0.07%	224
2024 Q1	$11.6M	Buy	133,383 +128,549	+2,659%	+$11.5M	0.38%	87
2023 Q4	$466K	Buy	+4,834	New	+$428K	0.02%	266
2021 Q1	–	Sell	-5,811	Closed	-$510K	–	440
2020 Q4	$510K	Buy	+5,811	New	+$461K	0.03%	277
2020 Q3	–	Sell	-2,183	Closed	-$269K	–	312
2020 Q2	$269K	Buy	+2,183	New	+$217K	0.02%	240
2016 Q4	–	Sell	-41,500	Closed	-$3.84M	–	302
2016 Q3	$3.84M	Buy	+41,500	New	+$3.91M	0.22%	132
2016 Q2	–	Sell	-11,900	Closed	-$982K	–	331
2016 Q1	$982K	Buy	+11,900	New	+$968K	0.06%	224

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

EIM

Elliott Investment Management West Palm Beach, Florida $22.7B AUM 59.88% 1-Year Est. Return

J. Goldman & Co's BMRN Position: Q3 2024 in Review

J. Goldman & Co sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2024, closing a stake of 31,701 shares — an estimated $2.61M sold.

J. Goldman & Co first reported a position in BMRN in Q1 2016 and held it in 7 quarters. The position peaked at $11.6M in Q1 2024. 554 funds tracked by Wall St. Rank hold BMRN as of Q3 2024.

J. Goldman & Co reported no remaining BioMarin Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
J. Goldman & Co sold 31,701 BioMarin Pharmaceuticals shares in Q3 2024, an estimated $2.61M.
J. Goldman & Co first reported a position in BioMarin Pharmaceuticals in Q1 2016 and held it in 7 quarters.
J. Goldman & Co's BioMarin Pharmaceuticals position peaked at $11.6M in Q1 2024.
554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2024.

Based on J. Goldman & Co's 13F filing for Q3 2024, filed 14 Nov 2024.